Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus
- Status
- UnknownResults none
- Why it is watched
- non-weight indication: cerebrovascular
- Who it enrolls
- age 50 Years to no upper limit; no BMI minimum stated; conditions: Ischemic Stroke; Transient Ischemic Attack; Type 2 Diabetes Mellitus
- Interventions
- Liraglutide
- Conditions
- Ischemic Stroke; Transient Ischemic Attack; Type 2 Diabetes Mellitus
- Phase and size
- NA · 1708 participants
- Dates
- Start 2019-06-25
Primary completion 2023-12 - Sponsor
- First Affiliated Hospital of Jinan University (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Percentage of patients with the 90-day new stroke events (ischemic or hemorrhagic)90 days
02Eligibility
Who can take part
Inclusion Criteria: * Adult subjects (male or female ≥ 50 years); * Acute ischemic stroke patients (NIHSS ≤ 3 at the time of randomization) with type 2 diabetes mellitus within 24 hours of symptoms onset; * High-risk TIA patients (ABCD2 score ≥ 4 at the time of randomization) with type 2 diabetes mellitus within 24 hours of onset; * First stroke, or prior stroke without sequel (mRS score ≤ 1) and does not affect the NIHSS score; * Informed consent signed. Exclusion Criteria: * Diagnosis of hemorrhage brain disease on baseline head CT; * Iatrogenic and cardiogenic stroke; * Patients receiving thrombolysis or endovascular treatment; * Use of a GLP-1 analogue or any dipeptidyl peptidase-IV (DPP-IV) inhibitor within the 3 months prior to screening; * Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma (FMTC); * Patients with pancreatitis or previous history of pancreatitis, inflammatory bowel disease and gastroparesis; * Pregnant, lactating women,or patients who are likely to have a pregnancy and plan to have one; * Allergic to liraglutide or excipients; * Congestive heart failure (NYHA class III-IV); * Severe liver and kidney dysfunction (AST/ALT is 3 times higher than the normal upper limit, serum creatinine is 3 times higher than the normal upper limit); * Patients with malignant tumors who are expected to have a survival period of less than three months; * Participated in other clinical trials of drugs within 3 months; * Researchers believe that patients who are not suitable for this clinical study.
03Change log
Registry changes
No changes recorded since the trial was added.